UNITED THERAPEUTICS 'BUY,' TARGET PRICE RAISED

nalysts at First Albany reiterate their "buy" rating on United Therapeutics Corp (UTHR.NAS), while raising their estimates for the company. The target price has been raised from $77 to $85. In a research note published this morning, the analysts mention that the company has reported its 3Q:05 EPS significantly ahead of and SG&A expenses lower than the estimates. United Therapeutics' Remodulin sales during the quarter were substantially ahead of the estimates, the analysts say.
Newratings